The Food and Drug Administration rattled the biotech industry last week when it said it wouldn't even look at Moderna's application to market the first mRNA flu shot.

The FDA says it will now review a new m-r-n-a flu vaccine from Moderna.

The dispute centered over a 40,000-person clinical trial that concluded Moderna’s new vaccine was more effective in adults aged 50 and older than one of the standard flu shots used today.